IPN.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 18:35):

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...

Stats
Dzisiejszy wolumen	15 762.00
Średni wolumen	76 692.00
Kapitalizacja rynkowa	9.47B
EPS	€0 ( 2024-02-08 )
Następna data zysków	( €0 ) 2024-07-23
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	15.57
ATR14	€0.121 (0.11%)

Wolumen Korelacja

Długi: -0.18 (neutral)

Krótki: 0.89 (strong)

Signal:(64.931) Same movement expected

Ipsen SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ipsen SA Korelacja - Waluta/Towar

0.05
( neutral )

0.10
( neutral )

0.00
( neutral )

-0.09
( neutral )

0.32
( neutral )

-0.19
( neutral )

Ipsen SA Finanse

Annual	2023
Przychody:	€3.13B
Zysk brutto:	€2.56B (81.74 %)
EPS:	€7.79

FY	2023
Przychody:	€3.13B
Zysk brutto:	€2.56B (81.74 %)
EPS:	€7.79

FY	2023
Przychody:	€0
Zysk brutto:	€0 (0.00 %)
EPS:	€0

FY	2022
Przychody:	€3.03B
Zysk brutto:	€2.50B (82.56 %)
EPS:	€7.87

Financial Reports:

No articles found.

Ipsen SA

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.